CGTLive’s Weekly Rewind – April 29, 2022

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. ZUMA-7 Axi-Cel Superiority Calls for Treatment Paradigm Shift in R/R LBLC

The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.

2. CAR T-Cell Therapy Is Safe, Effective in Minorities, Study Finds

The real-world analysis addresses a clear gap in data from previous and ongoing cell therapy clinical trials.

3. FDA Clears Pfizer to Resume Phase 3 Gene Therapy Trial for Duchenne Muscular Dystrophy

The CIFFREO trial is underway in 11 countries but was halted in December 2021 amid safety concerns, including the death of a participant in a phase 1b study in the non-ambulatory cohort.

4. Two CAR NK Cell Therapies Show Safety, Efficacy for AML, NHL

NKX101 and NKX019 have demonstrated preliminary signs of safety and efficacy in heavily pretreated patients with AML and NHL in 2 separate phase 1 studies.

5. CAR T-Cell Therapy Effective Without Toxicity Risk in Patients With Primary/Secondary CNS Lymphoma

In this late-breaking poster presented at the Tandem Meetings, investigators recommend that patients with primary or secondary central nervous system lymphoma be included in future clinical trials for CAR T-cell therapy.